Dosing & Product Information

RUXIENCE has the same dosing and administration schedule as Rituxan® (rituximab)1

Indication/dosing chart.png

CVP=cyclophosphamide, vincristine, and prednisone; FC=fludarabine and cyclophosphamide.

Please see the full Prescribing Information for Important Dosing Considerations.

*Please see the Dosage and Administration section in the full Prescribing Information for additional details, including important dosing information, premedication and prophylactic medications, and administration and storage instructions.

For administration of Zevalin® (ibritumomab tiuxetan) for the treatment for NHL, please see the full Prescribing Information.

Please see the Dosage and Administration section in the full Prescribing Information for additional details, including recommended glucocorticoid administration and other dosing considerations.

§Follow-up dosing for patients who have achieved control with induction treatment.

Product Information

Vial icon
Available in 100 mg/10 mL SDVs and 500 mg/50 mL SDVs
Temperature icon
Store in the refrigerator at 2°-8° C (36°- 46° F)||
Carton icon
Keep in original carton and protect from light. Do not freeze or shake the vial or carton

SDV=single-dose vial.

||Diluted RUXIENCE solutions for infusion may be stored at 2°C to 8°C (36°F to 46°F) for 24 hours. Complete administration within 8 hours from removal from refrigeration. No incompatibilities between RUXIENCE and polyvinylchloride bags have been observed.

RUXIENCE 100 mg/10 mL and 500 mg/50 mL packaging image

Ordering Information

SDV and MDV Ordering Information

Coding Information4

HCPCS Code: Q5119; OPPS Status G(4)

OPPS=Outpatient Prospective Payment System.

NCCN Guidelines® recommend the use of an FDA-approved biosimilar as an appropriate substitute for rituximab. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

References:
  1. RUXIENCE [prescribing information]. New York, NY: Pfizer Inc.; May 2020.
  2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V.1.2021. © 2020 National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the guideline, go online to NCCN.org.
  3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V.1.2020. © 2020 National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the guideline, go online to NCCN.org.
  4. Centers for Medicare & Medicaid Services. July 2020 Update of the Hospital Outpatient Prospective Payment System (OPPS). Updated July 1, 2020.